Fendi Hand Luggage
19 /PRNewswire/ Intercell AG has retained Inclinix, Inc., to recruit volunteers for their Phase III clinical trial of a Travelers' Diarrhea (TD) vaccine system. The TD vaccine is in the form of a skin patch a novel method for delivering a vaccine that is especially compelling because it is needle free.
The successful Phase II study followed 170 healthy travelers aged 18 64 to Mexico and Guatemala. The study found that of the 59 individuals who received the vaccine, only three suffered from moderate or severe diarrhea, while 23 of the 111 receiving a placebo suffered from moderate or severe diarrhea, a 75 percent reduction (p=0.007). No vaccine related serious adverse events were reported.
Trek Study coordinators will be in contact with volunteers through a variety of online and print communications, building excitement and providing helpful study and travel information. Volunteers will receive Fendi Hand Luggage compensation of up to $1500 for participation, along with pre paid mobile phones and welcome kits with useful travel tools. In a groundbreaking effort to encourage group travel, the Trek Study also features a program that provides referral compensation to refer friends.
Inclinix, Inc. Announces Expansion of Regional Recruitment Manager Enrollment Support Team EffRx Signs Licensing Deal with Nycomed for Its Novel Effervescent Osteoporosis Drug EX101; EffRx Will Receive Payments up to $59 Million
Inclinix, a Wilmington, NC based clinical trial enrollment solutions provider, will utilize its innovative recruitment tactics to drive the enrollment of 1200 volunteers in the US and 600 in Western Europe beginning in April 2009.
"We are pleased that Intercell AG has chosen Inclinix as their partner for the TD study," says J. Tobin Geatz, President and CEO, Inclinix.
This year, approximately 55 million international travelers will visit countries where bacteria that cause TD are endemic, particularly Africa, Asia and Latin America, and nearly 20 million of those travelers develop TD. The effects extend beyond the acute symptoms of the disease; between 10 and 30 percent of those who develop TD will develop the chronic symptoms of irritable bowel syndrome. If approved, this would be the first vaccine for TD available in the US.
the prevention and treatment of infectious diseases with substantial unmet medical need. The Company develops antigens and adjuvants, which are derived from its proprietary technology platforms, and has in house GMP manufacturing capabilities. Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Merck Co., Inc., Wyeth, Sanofi Pasteur, Kirin, and the Statens Serum Institut.
Based on compelling Phase II safety and efficacy data, this pivotal Phase III trial will follow approximately 1800 healthy volunteers age 18+ to Mexico and Guatemala, beginning in April 2009. Volunteers will receive two doses of the TD vaccine or a placebo, two weeks apart, with the last dose at least seven days prior to travel. Volunteers will then be surveyed via diary and visits for 17 days. The purpose of this trial is to evaluate the efficacy of the TD vaccine system.
About Intercell AG
In order to build awareness of the Trek Study, Inclinix has developed partnerships with major travel and tourism websites. In addition, Recruitment Monitors in field enrollment experts will execute events in communities near investigators' sites. "Traditional media combined with a strong relevant social and mobile networking presence is a fundamental element of this Fendi Dotcom Click Price
Inclinix, Inc. Releases Next Generation Critical Population Research(R) (CPR) for Clinical Trial Investigator Site Selection and Patient Recruitment Teva Pharmaceutical Industries Limited (TEVA) and Lonza Inc. Link to Tap Biosimilar Fendi Bag Monogram
Intercell is listed on the Prime Market of the Vienna Stock Exchange under the symbol "ICLL"Inclinix, Inc. specializes in customized Phase I IV clinical trial enrollment solutions that deliver productive investigator sites and qualified patients resulting in successfully completed clinical trials for the pharmaceutical, biotech and medical device industry. (ZGEN) Forge Interferon Deal; ZymoGenetics Inc. to Get $105 Million
About the Trek Study
Intercell AG Partners with Inclinix Inc to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
Intercell AG is a growing biotechnology company which focuses on the design and development of novel vaccines for Fendi Luggage Sale
enrollment campaign," explains Diane Montross, Director of Patient Recruitment for Inclinix. "We are thrilled to be using such innovative solutions to get the message out. Social communication avenues allow Inclinix to reach a unique audience. We are defining the next patient recruitment landscape."
Fendi Hand Luggage
Fendi Credit Card WalletHome
Fendi White Tote Bag
Burberry Wallet Macy's
Burberry Backpack With Initials
Burberry Wallet Black
Fendi Monster Face Bag
Fendi Designer Handbags
Fendi Peekaboo Mini Black
Fendi Hobo Pequin
Burberry Bag Orange
Fendi Peekaboo Beige
Burberry Purse On Ebay
Fendi Backpack Karlito
Fendi Tote Bag Images
Fendi Duffle Bag Price
/ Fendi Hand Luggage